Emmanuelle Charafe Jauffret

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Targeting breast cancer stem cells: fishing season open!
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR Inserm Institut Paoli Calmettes, France
    Breast Cancer Res 12:312. 2010
  2. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
  3. pmc Genome profiling of ERBB2-amplified breast cancers
    Fabrice Sircoulomb
    Marseille Cancer Research Center, UMR891 Inserm, Institut Paoli Calmettes, Department of Molecular Oncology, Marseille, France
    BMC Cancer 10:539. 2010
  4. pmc Nectin-4 is a new histological and serological tumor associated marker for breast cancer
    Stéphanie Fabre-Lafay
    INSERM, UMR599, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 7:73. 2007
  5. pmc Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin
    Azza Ben Hamida
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm, Marseille, France
    BMC Cancer 8:28. 2008
  6. pmc Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
    Anne Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:245. 2006
  7. ncbi request reprint Characterization of Hodgkin's lymphoma-like undifferentiated carcinoma of the nasopharyngeal type as a particular UCNT subtype mimicking Hodgkin's lymphoma
    Emmanuelle Charafe-Jauffret
    Department of Pathology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, BP 156, F 13273 Marseille cedex 9, France
    Int J Oncol 23:97-103. 2003
  8. pmc Cancer stem cells in breast: current opinion and future challenges
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Pathobiology 75:75-84. 2008
  9. ncbi request reprint Vertebral metastases from pineoblastoma
    E Charafe-Jauffret
    Department of Pathology, Centre Régional de Lutte contre le Cancer Institut Paoli Calmettes, Marseille, France
    Arch Pathol Lab Med 125:939-43. 2001
  10. pmc Breast cancer stem cells: tools and models to rely on
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 9:202. 2009

Collaborators

Detail Information

Publications33

  1. pmc Targeting breast cancer stem cells: fishing season open!
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR Inserm Institut Paoli Calmettes, France
    Breast Cancer Res 12:312. 2010
    ..A large research effort is now aiming to develop drugs targeting CSCs, based either on a priori understanding of key pathways regulating CSC biology or on high-throughput screening to identify novel targets and compounds...
  2. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
    ..We searched for prognostic and predictive markers for docetaxel's benefit...
  3. pmc Genome profiling of ERBB2-amplified breast cancers
    Fabrice Sircoulomb
    Marseille Cancer Research Center, UMR891 Inserm, Institut Paoli Calmettes, Department of Molecular Oncology, Marseille, France
    BMC Cancer 10:539. 2010
    ..They are associated with a poor prognosis but can benefit from targeted therapy. A better knowledge of these BCs, genomically and biologically heterogeneous, may help understand their behavior and design new therapeutic strategies...
  4. pmc Nectin-4 is a new histological and serological tumor associated marker for breast cancer
    Stéphanie Fabre-Lafay
    INSERM, UMR599, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 7:73. 2007
    ..Nectins are cell adhesion molecules involved in the regulation of epithelial physiology. We present here Nectin-4/PVRL4 as a new histological and serological tumor associated marker for breast carcinoma...
  5. pmc Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin
    Azza Ben Hamida
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm, Marseille, France
    BMC Cancer 8:28. 2008
    ..The aim of this study was to determine the distribution of molecular subtypes in IBC and identify factors that may explain the poor prognosis of IBC...
  6. pmc Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
    Anne Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:245. 2006
    ..Amplification status may provide diagnostic and prognostic information and may lead to new treatment strategies. Chromosomal regions 8p12, 8q24, 11q13, 17q12 and 20q13 are recurrently amplified in breast cancers...
  7. ncbi request reprint Characterization of Hodgkin's lymphoma-like undifferentiated carcinoma of the nasopharyngeal type as a particular UCNT subtype mimicking Hodgkin's lymphoma
    Emmanuelle Charafe-Jauffret
    Department of Pathology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, BP 156, F 13273 Marseille cedex 9, France
    Int J Oncol 23:97-103. 2003
    ..These results show that UCNT morphologically resembling HL share also some specific phenotypical and molecular features with HL, and might deserve to be isolated as a particular UCNT subtype...
  8. pmc Cancer stem cells in breast: current opinion and future challenges
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Pathobiology 75:75-84. 2008
    ..Following this approach, new molecules are currently in development. Focusing on the cross-talk between stem cells and their microenvironment is also a promising way to explore how to better target cancer stem cells and be curative...
  9. ncbi request reprint Vertebral metastases from pineoblastoma
    E Charafe-Jauffret
    Department of Pathology, Centre Régional de Lutte contre le Cancer Institut Paoli Calmettes, Marseille, France
    Arch Pathol Lab Med 125:939-43. 2001
    ..These uncommon cases are discussed with reference to the literature on extraneural metastases that originate from neuroepithelial tumors of the central nervous system...
  10. pmc Breast cancer stem cells: tools and models to rely on
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 9:202. 2009
    ..In this review, we survey tools and markers available or promising to identify breast CSCs. We review the main models used to study breast CSCs and how they challenge the CSC hypothesis...
  11. ncbi request reprint [Inflammatory breast carcinoma: towards molecular characterization?]
    Emmanuelle Charafe-Jauffret
    Département de biopathologie, Institut Paoli Calmettes, Marseille
    Ann Pathol 23:564-9. 2003
    ..It has been shown to be lost in IBC and could control tumor growth, invasion, and angiogenesis. This paper summarizes current knowledge on IBC and describes a new basis for a molecular definition of IBC...
  12. pmc Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer
    Emmanuelle Charafe-Jauffret
    Department of Molecular Oncology, Institut Paoli Calmettes UMR891 Institut National de la Sante et de la Recherche Medicale, Universite de la Mediterranee, Marseille Cancer Research Center, Marseille, France
    Clin Cancer Res 16:45-55. 2010
    ..To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this aggressive type of breast cancer...
  13. ncbi request reprint Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype
    Stephane Garcia
    Department of Pathology, Centre Hospitalo Universitaire Nord, 13916 Marseille, France
    Hum Pathol 38:830-41. 2007
    ....
  14. ncbi request reprint [Towards an integrated cellular and molecular: definition of breast cancers]
    Emmanuelle Charafe-Jauffret
    UMR 599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancérologie de Marseille et Université de la Méditerranée, 27, boulevard Lei Roure, 13009 Marseille, France
    Med Sci (Paris) 23:626-32. 2007
    ..These combined studies allow a new integrated cellular and molecular definition of breast cancers and a conceptual basis that will help the management of the disease...
  15. ncbi request reprint Inflammatory breast cancers in Tunisia and France show similar immunophenotypes
    Emmanuelle Charafe-Jauffret
    Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes et UMR599 Inserm, IFR137 Marseille, France
    Breast 16:352-8. 2007
    ..It is thought that IBC occurs with a high frequency in Tunisia. The aim of this study is to evaluate this signature on a Tunisian series...
  16. ncbi request reprint Identification and validation of an ERBB2 gene expression signature in breast cancers
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR119 Inserm, IFR57, and Faculté de Médecine, Universite de la Mediterranee, Marseille, France
    Oncogene 23:2564-75. 2004
    ..Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples...
  17. ncbi request reprint Integrated profiling of basal and luminal breast cancers
    José Adélaïde
    Marseille Cancer Research Center, Department of Molecular Oncology, Institut Paoli Calmettes and UMR599 Institut National de la Santé et de la Recherche Médicale, Marseille, France
    Cancer Res 67:11565-75. 2007
    ..Finally, among 10p candidate oncogenes associated with basal subtype, we validated CDC123/C10orf7 protein as a basal marker...
  18. ncbi request reprint Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis
    Stephane Garcia
    Department of Pathology, Centre Hospitalo Universitaire, Hopital Nord, Marseille, France
    Int J Oncol 31:49-58. 2007
    ....
  19. doi request reprint How different are luminal A and basal breast cancers?
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Marseille, France
    Int J Cancer 124:1338-48. 2009
    ....
  20. ncbi request reprint Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators
    Nathalie Conte
    Département d Oncologie Moléculaire, U119 INSERM, 27 Bd Lei Roure, 13009, Marseille, France
    Oncogene 21:5619-30. 2002
    ..We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes...
  21. doi request reprint Defining the molecular biology of inflammatory breast cancer
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR599 INSERM, IFR137, 232 Boulevard Sainte Marguerite, Marseille Cedex 09, France
    Semin Oncol 35:41-50. 2008
    ..The aim of this review is to present and discuss what is known about the biology of this particularly aggressive form of breast cancer and to discuss how this knowledge could improve its management...
  22. ncbi request reprint Moesin expression is a marker of basal breast carcinomas
    Emmanuelle Charafe-Jauffret
    Laboratory of Molecular Oncology, Marseille Cancer Research Institute, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    Int J Cancer 121:1779-85. 2007
    ..014). In multivariate analysis, Moesin expression was nearly an independent prognostic marker of poor outcome as shown by Cox proportional hazard model in patients without lymph node metastasis (p = 0.052, HR = 2.38, CI 95[0.99-5.69])...
  23. ncbi request reprint Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Int J Cancer 107:854-62. 2003
    ..37 (1.21-4.64; p = 0.03). Thus, among the patients who present with tumors of apparent good prognosis, FHIT is an independent prognostic factor that distinguishes a subgroup of patients who could benefit from adjuvant treatment...
  24. ncbi request reprint [Small but high throughput: how "tissue-microarrays" became a favorite tool for pathologists and scientists]
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, 232 Bd de Sainte Marguerite, 13273 Marseille Cedex 9, France
    Ann Pathol 23:623-32. 2003
    ..This Article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research...
  25. ncbi request reprint Typical medullary breast carcinomas have a basal/myoepithelial phenotype
    Jocelyne Jacquemier
    Marseille Cancer Institute, Molecular Oncology Department, UMR599 INSERM and Paoli Calmettes Institute, Marseille, France
    J Pathol 207:260-8. 2005
    ..In multivariate analysis with logistic regression, TMBC was defined by the association of P-cadherin (R=2.29), MIB1 > 50 (R=3.80), ERBB2 negativity (R=2.24) and p53 positivity (RR=1.45)...
  26. pmc Constitutive nuclear localization and initial cytoplasmic apoptotic activation of endogenous caspase-3 evidenced by confocal microscopy
    Olivier Ramuz
    INSERM U119, Service d Anatomie et Cytologie Pathologiques, Laboratoire d Immunologie des Tumeurs, Institut Paoli Calmettes, IFR 57 and Université de la Méditerranée, Marseille, France
    Int J Exp Pathol 84:75-81. 2003
    ..These results provide new perspectives about the subcellular compartmentation and traffic of caspases during the apoptotic process...
  27. doi request reprint [Radiotherapy in adult glioblastomas]
    P Y Bondiau
    Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06100 Nice, France
    Neurochirurgie 56:486-90. 2010
    ..After a review of the physical and biological bases of ionizing radiation, we present the techniques, results, side effects, and results of irradiation of glioblastomas...
  28. ncbi request reprint ETV6 gene rearrangements in invasive breast carcinoma
    Anne Letessier
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Institut Paoli Calmettes and UMR599 INSERM, Marseille, France
    Genes Chromosomes Cancer 44:103-8. 2005
    ..Of these samples, signal of sufficient quality for screening by FISH was obtained for 356. Five cases (one lobular, one nontypical secretory, one mixed, and two ductal carcinomas) showed ETV6 rearrangement...
  29. ncbi request reprint Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene
    Cornel Popovici
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, Marseille, France
    Genes Chromosomes Cancer 35:204-18. 2002
    ..Additional experiments using comparative genomic hybridization provided further information on the genomic context in which the t(3;20)(p14;p11) reciprocal translocation was found...
  30. pmc Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes
    Anthony Goncalves
    Department of Molecular Pharmacology, Marseille Research Cancer Center, Marseille, France
    Mol Cell Proteomics 7:1420-33. 2008
    ..Our study shows the potential of integrated genomics and proteomics profiling to improve molecular knowledge of complex tumor phenotypes and identify biomarkers with valuable diagnostic or prognostic values...
  31. doi request reprint Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis
    Pascal Finetti
    UMR599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Cancer Res 68:767-76. 2008
    ..The identification of luminal A cases of poor prognosis should help select appropriate treatment, whereas the identification of a relevant kinase set provides potential targets...
  32. ncbi request reprint Chromosome arm 8p and cancer: a fragile hypothesis
    Daniel Birnbaum
    Department of Molecular Oncology, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Lancet Oncol 4:639-42. 2003
    ..We have found that chromosome breaks disrupt the NRG1 gene at 8p12 in breast and pancreatic cancers. We hypothesise that alteration of the NRG1 gene could occur through breakage at a non-common fragile site...
  33. ncbi request reprint Basal and luminal breast cancers: basic or luminous? (review)
    Daniel Birnbaum
    Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and UMR599 INSERM, 13009 Marseille, France
    Int J Oncol 25:249-58. 2004
    ..The combined effects of these progresses on our understanding of breast cancer biology should have major consequences on the way this disease is managed...